Potent and selective V1B receptor antagonist (IC50 = 2.22 nM for rat pituitary receptor). Exhibits no significant affinity for 85 other receptors, ion channels and transporters at 10 μM, including V1A and V2. Increases ACTH levels in rats. Orally bioavailable. Antidepressant and anxiolytic.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 554.44. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.8 mL||9.02 mL||18.04 mL|
|5 mM||0.36 mL||1.8 mL||3.61 mL|
|10 mM||0.18 mL||0.9 mL||1.8 mL|
|50 mM||0.04 mL||0.18 mL||0.36 mL|
References are publications that support the products' biological activity.
Iijima et al (2014) Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325. Br J Pharmacol. 171 3511 PMID: 24654684
If you know of a relevant reference for TASP 0390325, please let us know.
View Related Products by Product Action
Keywords: TASP 0390325, supplier, TASP0390325, vasopressin, receptors, antagonists, antagonism, potent, selective, V1B, anxiolytic, antidepressant, Vasopressin, Receptors, Vasopressin, Receptors, Tocris Bioscience
Citations for TASP 0390325
Citations are publications that use Tocris products.
Currently there are no citations for TASP 0390325. Do you know of a great paper that uses TASP 0390325 from Tocris? If so please let us know.
TASP 0390325 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.